Temporomandibular joint involvement in patients with multiple myeloma—a retrospective study

Autor: Abboud, W., Yahalom, R., Leiba, M., Greenberg, G., Yarom, N.

Publikováno v: In International Journal of Oral & Maxillofacial Surgery December 2016 45(12):1545-1550

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Four-year follow-up of the phase 3 POLLUX study of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in relapsed or refractory multiple myeloma

Autor: Cook, G Kaufman, JL Usmani, SZ San-Miguel, J Bahlis, NJ White, D Benboubker, L Leiba, M Ho, PJ Kim, K others

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::16800c0bf32fcd2d282e551e109732f0
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2955041

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Autor: Kaufman, J.L. Dimopoulos, M.A. White, D. Benboubker, L. Cook, G. Leiba, M. Morton, J. Joy Ho, P. Kim, K. Takezako, N. Moreau, P. Sutherland, H.J. Magen, H. Iida, S. Kim, J.S. Miles Prince, H. Cochrane, T. Oriol, A. Bahlis, N.J. Chari, A. O’Rourke, L. Trivedi, S. Casneuf, T. Krevvata, M. Ukropec, J. Kobos, R. Avet-Loiseau, H. Usmani, S.Z. San-Miguel, J.

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::ae5707ad11d0c7f0100e327bede71f29
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103651

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX

Autor: Kaufman, J. L., Dimopoulos, M., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Joy Ho, P., Kim, K., Takezako, N., Moreau, P., Sutherland, H. J., Magen, H., Iida, S., Kim, J. S., Miles Prince, H., Cochrane, T., Oriol, Albert, Bahlis, N. J., Chari, A., O'Rourke, L., Trivedi, S., Casneuf, T., Krevvata, M., Ukropec, J., Kobos, R., Avet-Loiseau, H., Usmani, S. Z., San-Miguel, J., Universitat Autònoma de Barcelona

Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Blood Cancer Journal, Vol 10, Iss 11, Pp 1-10 (2020)
Blood Cancer Journal
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf52c1b21c245ed4d385bb3826621820
https://ddd.uab.cat/record/236598